Adult: Each g of cream contains betamethasone valerate 1.22 mg (equivalent to betamethasone 1 mg) and clioquinol 30 mg
Each g of ointment contains betamethasone valerate 1.22 mg (equivalent to betamethasone 1 mg) and clioquinol 30 mg
In cases where secondary bacterial or fungal infection is present: Apply thinly to the affected area bid or tid until improvement occurs. If improvement in symptoms is observed, may decrease application to once daily or even less often. Discontinue treatment if there is no clinical response after 7 days. Treatment recommendations and available dosage strengths may vary among countries and between individual products (refer to specific product guidelines). Child: Same as adult dose. If possible, limit treatment to 5 days. Treatment recommendations and available dosage strengths may vary among countries and between individual products (refer to specific product guidelines).
Chống chỉ định
Hypersensitivity to betamethasone or clioquinol. Viral skin infections (e.g. herpes simplex, varicella zoster), rosacea, acne vulgaris, perioral dermatitis, perianal or genital pruritus, primary infected skin lesions caused by infection with bacteria (e.g. impetigo) or fungi (e.g. candidiasis, tinea), primary or secondary infections due to yeast; dermatoses in children <1 year including diaper rash and dermatitis.
Thận trọng
Patient with psoriasis or thyroid disease. Not intended for use in patients with widespread plaque psoriasis. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypercortisolism or HPA axis suppression (particularly in younger children or in patients receiving high doses for prolonged periods); ocular effects (e.g. posterior subcapsular cataract, glaucoma); immunosuppression, superinfection (prolonged use); may cause neurotoxicity (particularly when used with occlusive dressings or for extended period); topical steroid withdrawal reactions (particularly after discontinuation of ≥6 months long-term use), may be manifested as severe redness which can spread beyond the initial affected area, itching, burning or stinging sensation, and skin peeling. Rarely, irritation. Skin and subcutaneous tissue disorders: Pruritus, local skin burning or pain.
Thông tin tư vấn bệnh nhân
Avoid contact with eyes. This drug may stain or discolour hair, skin and fabrics. In case of long-term use (≥6 months): Inform the doctor immediately if severe redness which can spread beyond the initial affected area, itching, burning or stinging sensation, and skin peeling occur after treatment discontinuation.
Chỉ số theo dõi
Observe growth in children. Monitor the affected area for signs or symptoms of increased irritation.
Tương tác
Betamethasone: Concomitant use with CYP3A4 inhibitors (e.g. ritonavir, itraconazole) may inhibit betamethasone metabolism, thus resulting in increased systemic exposure.
Ảnh hưởng đến kết quả xét nghiệm
May interfere with iodine-uptake thyroid function test. May cause false-positive ferric chloride test for phenylketonuria.
Tác dụng
Description: Mechanism of Action: Betamethasone is a corticosteroid with primarily glucocorticoid activity. It may suppress the formation, release, and activity of endogenous inflammatory mediators (e.g. kinins, histamine, liposomal enzymes, prostaglandins) by inducing phospholipase A2 inhibitory proteins (lipocortins) and subsequently inhibiting the release of arachidonic acid. Potency of betamethasone may vary from moderately to very potent depending on the dosage form.
Clioquinol, a halogenated hydroxyquinoline, is a broad-spectrum antibacterial and antifungal agent. It chelates the bacterial surface and trace metals necessary for bacterial growth. Pharmacokinetics: Absorption: Betamethasone: Absorbed percutaneously. Metabolism: Betamethasone: Metabolised in the liver. Excretion: Betamethasone: Via urine and bile.
Đặc tính
Betamethasone Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9782, Betamethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Betamethasone. Accessed Sept. 24, 2024.
Clioquinol Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2788, Iodochlorhydroxyquin. https://pubchem.ncbi.nlm.nih.gov/compound/Iodochlorhydroxyquin. Accessed May 28, 2025.
D07BC01 - betamethasone and antiseptics ; Belongs to the class of potent (group III) corticosteroids, in combination with antiseptics. Used in the treatment of dermatological diseases.
Tài liệu tham khảo
Betamethasone (Topical). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 10/02/2025.Betamethasone and Clioquinol. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 10/02/2025.Betamethasone Valerate/Clioquinol 1 mg/30 mg/g Cream (Chemidex Pharma Ltd). MHRA. https://products.mhra.gov.uk. Accessed 10/02/2025.Betamethasone Valerate/Clioquinol 1 mg/30 mg/g Ointment (Chemidex Pharma Ltd). MHRA. https://products.mhra.gov.uk. Accessed 10/02/2025.Brayfield A, Cadart C (eds). Betamethasone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2025.Brayfield A, Cadart C (eds). Clioquinol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2025.Joint Formulary Committee. Betamethasone with Clioquinol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2025.Topical Corticosteroids: Information on the Risk of Topical Steroid Withdrawal Reactions. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/drug-safety-update. Accessed 20/05/2025.Topical Steroids: Introduction of New Labelling and a Reminder of the Possibility of Severe Side Effects, Including Topical Steroid Withdrawal Reactions. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/drug-safety-update. Accessed 20/05/2025.
Đăng xuất
Tiếp tục với Google